Pharmaceuticals, Biotechnology & Life Sciences

Explore why Ningbo Menovo Pharmaceutical, a quiet Chinese API maker, may hold hidden value amid China’s push for drug self‑sufficiency.

Nurix Therapeutics reports Q2 2026 earnings miss, but highlights Roche partnership and protein‑level modulation pipeline, signaling continued focus on innovative treatments.

ATAI Life Sciences NV’s AtaiBeckley Inc. plans a $5.17‑share sale of 100,000 shares by a director, revealing key financial strategy and compliance for investors.

Amgen shares slip 2% on July 9, 2026 while Nasdaq climbs, amid FDA approval of a new oncology biosimilar that could reshape the biotech race.

Satellos Bioscience’s interim TRAILHEAD data show significant fat‑fraction reduction, improved endurance, and low CK levels—hinting at a breakthrough DMD therapy that’s boosting analyst optimism and stock upside.

Recursion Pharmaceuticals sells 200k shares as insider Gibson divests amid a $3.72 stock price and negative P/E, highlighting investor uncertainty and a tech‑driven biotech pivot.

Vertex’s $10 B takeover of Crinetics expands its portfolio into endocrinology, adding Phase III assets and boosting revenue potential.

VeraDermics: A $5.1B biopharma eyeing dermatology breakthroughs amid sharp stock swings, a negative P/E, and fierce competition.

Schott Pharma’s 2026 Q3 surge and upward revenue outlook boost shares, showing strong drug‑delivery growth and solid future value for life‑science investors.

Relief Therapeutics Holding AG: Swiss biopharma focused on rare metabolic, pulmonary, and connective tissue disorders, trading on SIX with a $28M market cap.